Mark S. Kleven
Directeur des opérations chez Neurolixis, Inc.
Profil
Mark S.
Kleven is currently the Operations Director at Neurolixis, Inc. He previously worked as the Vice President-PreClinical Development at Ceptaris Therapeutics, Inc., Head-Behavioral Pharmacology at Physicians Formula Holdings, Inc., and Principal at The University of Chicago.
He earned a doctorate degree from the University of Minnesota in 1986.
Postes actifs de Mark S. Kleven
| Sociétés | Poste | Début |
|---|---|---|
Neurolixis, Inc.
 Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Directeur des opérations | - |
Anciens postes connus de Mark S. Kleven
| Sociétés | Poste | Fin |
|---|---|---|
Physicians Formula Holdings, Inc.
 Physicians Formula Holdings, Inc. Specialty StoresRetail Trade Physicians Formula Holdings, Inc. engages in the development, marketing, and sale of cosmetic and skin care products. The company was founded in 1937 and is headquartered in Azusa, CA. | Corporate Officer/Principal | - |
| The University of Chicago | Corporate Officer/Principal | - |
Ceptaris Therapeutics, Inc.
 Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Corporate Officer/Principal | - |
Formation de Mark S. Kleven
| University of Minnesota | Doctorate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Ceptaris Therapeutics, Inc.
Ceptaris Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Ceptaris Therapeutics, Inc. develops mechlorethamine gels. The firm develops a gel formulation of mechlorethamine hydrochloride for the treatment of early stage (stages I-IIA) mycosis fungoides, a type of Cutaneous T-Cell Lymphoma. The company was founded in 2002 and is headquartered in Malvern, PA. | Health Technology |
Physicians Formula Holdings, Inc.
Physicians Formula Holdings, Inc. Specialty StoresRetail Trade Physicians Formula Holdings, Inc. engages in the development, marketing, and sale of cosmetic and skin care products. The company was founded in 1937 and is headquartered in Azusa, CA. | Retail Trade |
Neurolixis, Inc.
Neurolixis, Inc. Miscellaneous Commercial ServicesCommercial Services Neurolixis, Inc. is an early-stage biopharmaceutical company that focuses on discovering and developing novel drugs for the treatment of central nervous system disorders such as Parkinson's disease, Rett syndrome, depression, and pain. Neurolixis is based in Dana Point, CA. The private company is developing a platform of early-stage drug candidates that target serious CNS diseases with unmet medical needs and a sizable market opportunity. The company's compounds are based on the concept of serotonin 5-HT1A receptor "biased agonism," which enables drugs to more precisely target specific brain regions controlling CNS disorders. The company was founded by Mark A. Varney and Adrian Newman-Tancredi, and Adrian Newman-Tancredi has been the CEO since incorporation. | Commercial Services |
